Evidence map›Paper›PMID 42688348›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026

[CAMK2a Regulates Paclitaxel Resistance in Oral Squamous Cell Carcinoma Cells by Activating the ERK Signaling Pathway].

Junfeng Wang, Hongli Chen, Jiao Chen, Yun Feng, Yao Yuan, Ping Zhang

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Junfeng Wang（ 610041）State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.ORCID 0009-0000-1030-8795
Hongli Chen（ 610041）State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Jiao Chen（ 610041）State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Yun Feng（ 610041）State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Yao Yuan（ 610041）State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Ping Zhang（ 610041）State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.ORCID 0000-0002-2344-3336

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the molecular mechanisms by which calcium signaling pathways regulate the paclitaxel resistance and the survival of oral squamous cell carcinoma (OSCC) cells. Methods: A paclitaxel-resistant OSCC cell model was established through continuous low-dose paclitaxel induction with dose escalation. The stability of the paclitaxel-resistant model was assessed using the Cell Counting Kit-8 (CCK-8) and imaging flow cytometry. RNA sequencing (RNA-seq) was performed to analyze differentially expressed genes and functional enrichment. Quantitative real-time PCR (qPCR) was conducted to analyze the differential expression of the Results: A paclitaxel-resistant OSCC cell model was successfully established. Gene Ontology (GO) enrichment analysis of the sequencing data revealed differences in the calcium signaling pathways in resistant cells. The expression of multiple genes of the CAMK2 family was upregulated, and Conclusion: CAMK2a regulates drug resistance and the proliferative capacity of paclitaxel-resistant cells by activating the MAPK-Erk1/2 pathway and represents a potential new therapeutic target for clinical treatment of drug-resistant patients.

Indexed as

Calcium-Calmodulin-Dependent Protein Kinase Type 2Carcinoma, Squamous CellDrug Resistance, NeoplasmMAP Kinase Signaling SystemMouth NeoplasmsPaclitaxelCell Line, TumorGene Expression Regulation, NeoplasticHumansRNA, Small InterferingCalcium-Calmodulin-Dependent Protein Kinase Type 2PaclitaxelRNA, Small InterferingCalcium signaling pathwayCAMK2aOral squamous cell carcinomaPaclitaxel resistanceTarget

Identifiers

PMID42688348
PMCPMC13534574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.